MedTrace Logo

Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.

NCT03455387 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 233

Last updated 2022-06-14

No results posted yet for this study

Summary

The pre-eclampsia is a frequent pathology, concerning approximately 5 % of the pregnancies.The pre-eclampsia can evolve into severe maternal and\\or foetal complications and is a major cause of mortality.

The purpose of the study will to estimate the relevance of the serum markers sFlt1 and PlGF to predict the arisen of severe complications at these patients, what would allow to decrease the materno-fœtale morbi-mortality due to the pathology.

Conditions

  • Pre-Eclampsia
  • HELLP Syndrome
  • Fetal Death
  • Eclampsia
  • Placental Abruption
  • Fetal Growth Retardation, Antenatal

Interventions

DIAGNOSTIC_TEST

sampling of the serum marker sFlt1 and PlGF

sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery

Sponsors & Collaborators

  • Centre Hospitalier Metropole Savoie

    lead OTHER

Principal Investigators

  • Christophe DOCHE · Centre Hospitalier Metropole Savoie

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-10
Primary Completion
2019-12-20
Completion
2019-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03455387 on ClinicalTrials.gov